Investigating how Imidazole Propionate affects Alzheimer’s Disease and related dementias
Official title: Exploring the role of Imidazole Propionate on Alzheimer’s Disease and Related Dementias
Funded at University of Wisconsin-Madison · NIH-11174537 · Data updated 2026-11-12
This study is looking at how a substance made by gut bacteria, called imidazole propionate, might affect brain health and memory in people with Alzheimer's and related conditions, to see if changes in gut bacteria could play a role in cognitive decline.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | September 1, 2024 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $184,385 |
| NIH project number | 5R21AG089348-02 |
| Project ID | NIH-11174537 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals aged 65 and older who may be experiencing cognitive decline or are at risk for Alzheimer’s Disease.
✕Less likely to help
Patients under the age of 65 or those without any cognitive impairment may not benefit from this research.
What this research studies
This research explores the connection between a gut microbiome-derived metabolite called imidazole propionate and its impact on Alzheimer's Disease (AD) and related dementias (ADRD). The study aims to understand how changes in gut bacteria may influence brain health, particularly through effects on blood vessel function and neurodegeneration. By examining the levels of imidazole propionate in the blood and its relationship with cognitive decline, the research seeks to uncover potential mechanisms that contribute to AD pathology. Patients may be involved in assessments that measure cognitive function and biomarkers related to brain health.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or slowing the progression of Alzheimer’s Disease and related dementias.
How similar studies have gone: Previous research has shown promising results in understanding the role of gut microbiota in neurodegenerative diseases, suggesting that this approach may yield valuable insights.
Where this research is happening
-
University of Wisconsin-Madison
Madison, United States Active
Researchers
- Principal investigator: Rey, Federico E — University of Wisconsin-Madison
- Study coordinator: Rey, Federico E
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.